Sign in

You're signed outSign in or to get full access.

Damien Choplain

Damien Choplain

Research Analyst at Stifel Financial Corp.

Paris, FR

Damien Choplain is Managing Director and Co-Head of European Healthcare and Technology Research at Stifel, specializing in equity research and strategic advisory for the healthcare and biotechnology sectors. He has extensive coverage of major European pharma, biotech, and medtech companies, leveraging nearly 15 years of experience that includes roles as Senior Pharma/Biotech Analyst at Oddo BHF and as a sector analyst at Kepler Cheuvreux. Choplain joined Stifel in 2025 after previous tenures at Gilbert Dupont (Société Générale CIB) and Bionest Partners, and holds a master’s degree in chemistry from CPE Lyon and a Specialized Master’s in Corporate Finance from Emlyon Business School. His track record spans advisory on numerous significant transactions and recognition as a leading sector expert across European healthcare equities, though specific quantitative performance metrics are not publicly disclosed.

Damien Choplain's questions to Valneva (VALN) leadership

Question · Q2 2025

Damien Choplain from Stifel asked about potential triggers for accelerating IXCHIQ sales in the traveler market, the status of U.S. state stockpiling discussions, and the expected financial impact of the new distribution agreement with CSL Seqirus.

Answer

CEO Thomas Lingelbach stated that the CSL Seqirus agreement has similar commercial terms to the previous one, so no immediate financial difference is expected. Regarding IXCHIQ, he noted that the recent lifting of safety restrictions should create new momentum for market uptake and that discussions, including those for outbreak response, are expected to resume.

Ask follow-up questions

Fintool

Fintool can predict Valneva logo VALN's earnings beat/miss a week before the call